Patheon Special Committee Provides Update on Ontario Securities Commission Proceedings

    TORONTO, April 6 /CNW/ - As previously announced, on March 26, 2009 the
Special Committee of Independent Directors of Patheon Inc. ("Patheon")
(TSX:PTI), delivered a request to the Ontario Securities Commission ("OSC")
asking the OSC to review the legality of the unsolicited offer (the "Offer")
by JLL Patheon Holdings LLC ("JLL") to acquire any and all of the issued and
outstanding restricted voting shares (the "Restricted Voting Shares") of
Patheon not owned by JLL or its affiliates. In its offering circular, JLL
disclosed that, through a separate side deal, it is giving an option to
receive special rights and protections to a group of Patheon shareholders (the
"MOVA Group"), led by Joaquin Viso, who received Restricted Voting Shares when
Patheon acquired MOVA Pharmaceutical Corporation in 2004.
    The Special Committee has been advised by OSC staff that the OSC has
received an application from JLL requesting a discretionary exemption from
requirements relating to identical consideration and prohibitions against
collateral agreements contained in the take-over bid provisions of Canadian
securities laws. The Special Committee understands, from discussions with OSC
staff, that OSC staff has requested that the OSC consider this application
this week.
    The Special Committee believes that it would be prejudicial to the public
interest for the OSC to grant the requested relief. The Special Committee
intends to actively oppose JLL's application and believes that such relief
should not be granted without a full public hearing on both the application
and the matters set out in Patheon's previously disclosed complaint to the


    Patheon Inc. (TSX:PTI; is a leading global provider of
contract development and manufacturing services to the global pharmaceutical
industry. Patheon prides itself in providing the highest quality products and
services to more than 300 of the world's leading pharmaceutical and
biotechnology companies. Patheon's services range from preclinical development
through commercial manufacturing of a full array of dosage forms including
parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative
technologies including single-use disposables, Liquid-Filled Hard Capsules and
a variety of modified release technologies.
    Patheon's comprehensive range of fully integrated Pharmaceutical
Development Services includes pre-formulation, formulation, analytical
development, clinical manufacturing, scale-up and commercialization. Patheon
can take customers direct to clinic with global clinical packaging and
distribution services and Patheon's Quick to Clinic(TM) programs can
accelerate early phase development project to clinical trials while minimizing
the consumption of valuable API.
    Patheon's integrated development and manufacturing network of 11
facilities, and 6 development centers across North America and Europe, strives
to ensure that customer products can be launched with confidence anywhere in
the world.

For further information:

For further information: Special Committee: Information Agent for the
Special Committee, Kingsdale Shareholder Services, 1-866-851-3212; Media: John
Lute, Lute & Company, (416) 929-5883, email

Organization Profile

Patheon Inc

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890